An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
NCT ID: NCT00355901
Last Updated: 2008-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
300 participants
OBSERVATIONAL
2006-09-30
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
NCT00502294
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
NCT00279435
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
NCT03558152
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
NCT00279422
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
NCT02118584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Visilizumab (Nuvion®; HuM291)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy.
Exclusion Criteria
* For U.S. sites, unwilling or unable to provide authorization to use protected health information.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PDL BioPharma, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco, California, United States
Gainesville, Florida, United States
Atlanta, Georgia, United States
Louisville, Kentucky, United States
Worcester, Massachusetts, United States
Rochester, Minnesota, United States
St Louis, Missouri, United States
Manhasset, New York, United States
Mineola, New York, United States
New York, New York, United States
New York, New York, United States
Cleveland, Ohio, United States
Hershey, Pennsylvania, United States
Charleston, South Carolina, United States
Salt Lake City, Utah, United States
Bedford Park, South Australia, Australia
Box Hill, Victoria, Australia
Fremantle, , Australia
Liverpool, , Australia
Vienna, , Austria
Ghent, , Belgium
Leuven, , Belgium
Roeselare, , Belgium
Winnipeg, Manitoba, Canada
Hamilton, Ontario, Canada
Brno, , Czechia
Prague, , Czechia
Amiens, , France
Lille, , France
Paris, , France
Freiburg im Breisgau, , Germany
Béri Balogh Adám, , Hungary
Vác, , Hungary
Vásvari Pál, , Hungary
Dublin, , Ireland
Bologna, , Italy
Amsterdam, , Netherlands
Oslo, , Norway
Tromsø, , Norway
Kharkiv, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
291-420
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.